ID

27853

Description

Study of Telbivudine in Chronic Hepatitis B; ODM derived from: https://clinicaltrials.gov/show/NCT00970216

Link

https://clinicaltrials.gov/show/NCT00970216

Keywords

Versions (1)
  1. 12/1/17 12/1/17 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

December 1, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Hepatitis B NCT00970216

English

Eligibility Chronic Hepatitis B NCT00970216

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. male or female, at least 18 years of age.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. documented chronic hepatitis b defined by all of the following:
Description

Hepatitis B, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0524909
clinical history compatible with chronic hepatitis b.
Description

Medical History Consistent with Chronic Hepatitis B

Data type

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C0524909
detectable serum hepatitis b surface antigen >= 6 months at screening visit, with either hbeag positive or negative.
Description

Hepatitis B Surface Antigens Detectable | Hepatitis B e antigen positive | Hepatitis B e antigen negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0019168
UMLS CUI [1,2]
C3830527
UMLS CUI [2]
C0392390
UMLS CUI [3]
C0948827
3. willing and able to comply with the observational drug regimen and all other study requirements.
Description

Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0525058
4. willing and able to provide written informed consent to participate in the study.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. females who are pregnant,intending to become pregnant or breast feeding.
Description

Pregnancy | Pregnancy, Planned | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0032992
UMLS CUI [3]
C0006147
2. patients with co-infection with hepatitis c virus, hepatitis d virus or human immunodeficiency virus.
Description

HCV coinfection | HDV Coinfection | HIV coinfection

Data type

boolean

Alias
UMLS CUI [1]
C1698259
UMLS CUI [2,1]
C0011220
UMLS CUI [2,2]
C0275524
UMLS CUI [3]
C4062778
3. patients with hypersensitivity to telbivudine or to any of the excipients.
Description

Hypersensitivity telbivudine | Hypersensitivity Telbivudine Excipient

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1453933
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1453933
UMLS CUI [2,3]
C0015237
4. one or more known primary or secondary causes of liver disease other than hepatitis b (e.g., alcoholism, steatohepatitis, autoimmune hepatitis, hemochromatosis, alpha-1 anti-trypsin deficiency, wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease). gilbert's syndrome and dubin-johnson syndrome will not exclude patients from participation in this trial.
Description

Cause Primary Quantity Liver disease | Cause Secondary Quantity Liver disease | Exception Hepatitis B | Alcoholic Intoxication, Chronic | Steatohepatitis | Hepatitis, Autoimmune | Hemochromatosis | alpha 1-Antitrypsin Deficiency | Hepatolenticular Degeneration | Condition Congenital Affecting Liver | Condition Metabolic Affecting Liver | Congestive heart failure | Cor pulmonale Severe | Gilbert syndrome allowed | Dubin Johnson syndrome allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C0015127
UMLS CUI [1,2]
C0205225
UMLS CUI [1,3]
C1265611
UMLS CUI [1,4]
C0023895
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0175668
UMLS CUI [2,3]
C1265611
UMLS CUI [2,4]
C0023895
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0019163
UMLS CUI [4]
C0001973
UMLS CUI [5]
C2711227
UMLS CUI [6]
C0241910
UMLS CUI [7]
C0018995
UMLS CUI [8]
C0221757
UMLS CUI [9]
C0019202
UMLS CUI [10,1]
C0348080
UMLS CUI [10,2]
C1744681
UMLS CUI [10,3]
C0392760
UMLS CUI [10,4]
C0023884
UMLS CUI [11,1]
C0348080
UMLS CUI [11,2]
C0311400
UMLS CUI [11,3]
C0392760
UMLS CUI [11,4]
C0023884
UMLS CUI [12]
C0018802
UMLS CUI [13,1]
C0034072
UMLS CUI [13,2]
C0205082
UMLS CUI [14,1]
C0017551
UMLS CUI [14,2]
C0683607
UMLS CUI [15,1]
C0022350
UMLS CUI [15,2]
C0683607
5. enrolled or planning to be enrolled in another clinical trial of an investigational agent while participating in this study.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
6. unable to receive safety and tolerability assessments.
Description

Safety Assessment Receive Unable | Tolerability Study Receive Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0549076
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C1299582
UMLS CUI [2,1]
C3274448
UMLS CUI [2,2]
C1514756
UMLS CUI [2,3]
C1299582
Back to the top of the page

Similar models

Eligibility Chronic Hepatitis B NCT00970216

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. male or female, at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Hepatitis B, Chronic
Item
2. documented chronic hepatitis b defined by all of the following:
boolean
C0524909 (UMLS CUI [1])
Medical History Consistent with Chronic Hepatitis B
Item
clinical history compatible with chronic hepatitis b.
boolean
C0262926 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C0524909 (UMLS CUI [1,3])
Hepatitis B Surface Antigens Detectable | Hepatitis B e antigen positive | Hepatitis B e antigen negative
Item
detectable serum hepatitis b surface antigen >= 6 months at screening visit, with either hbeag positive or negative.
boolean
C0019168 (UMLS CUI [1,1])
C3830527 (UMLS CUI [1,2])
C0392390 (UMLS CUI [2])
C0948827 (UMLS CUI [3])
Protocol Compliance
Item
3. willing and able to comply with the observational drug regimen and all other study requirements.
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
4. willing and able to provide written informed consent to participate in the study.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Pregnancy, Planned | Breast Feeding
Item
1. females who are pregnant,intending to become pregnant or breast feeding.
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
HCV coinfection | HDV Coinfection | HIV coinfection
Item
2. patients with co-infection with hepatitis c virus, hepatitis d virus or human immunodeficiency virus.
boolean
C1698259 (UMLS CUI [1])
C0011220 (UMLS CUI [2,1])
C0275524 (UMLS CUI [2,2])
C4062778 (UMLS CUI [3])
Hypersensitivity telbivudine | Hypersensitivity Telbivudine Excipient
Item
3. patients with hypersensitivity to telbivudine or to any of the excipients.
boolean
C0020517 (UMLS CUI [1,1])
C1453933 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1453933 (UMLS CUI [2,2])
C0015237 (UMLS CUI [2,3])
Cause Primary Quantity Liver disease | Cause Secondary Quantity Liver disease | Exception Hepatitis B | Alcoholic Intoxication, Chronic | Steatohepatitis | Hepatitis, Autoimmune | Hemochromatosis | alpha 1-Antitrypsin Deficiency | Hepatolenticular Degeneration | Condition Congenital Affecting Liver | Condition Metabolic Affecting Liver | Congestive heart failure | Cor pulmonale Severe | Gilbert syndrome allowed | Dubin Johnson syndrome allowed
Item
4. one or more known primary or secondary causes of liver disease other than hepatitis b (e.g., alcoholism, steatohepatitis, autoimmune hepatitis, hemochromatosis, alpha-1 anti-trypsin deficiency, wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease). gilbert's syndrome and dubin-johnson syndrome will not exclude patients from participation in this trial.
boolean
C0015127 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0023895 (UMLS CUI [1,4])
C0015127 (UMLS CUI [2,1])
C0175668 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0023895 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0019163 (UMLS CUI [3,2])
C0001973 (UMLS CUI [4])
C2711227 (UMLS CUI [5])
C0241910 (UMLS CUI [6])
C0018995 (UMLS CUI [7])
C0221757 (UMLS CUI [8])
C0019202 (UMLS CUI [9])
C0348080 (UMLS CUI [10,1])
C1744681 (UMLS CUI [10,2])
C0392760 (UMLS CUI [10,3])
C0023884 (UMLS CUI [10,4])
C0348080 (UMLS CUI [11,1])
C0311400 (UMLS CUI [11,2])
C0392760 (UMLS CUI [11,3])
C0023884 (UMLS CUI [11,4])
C0018802 (UMLS CUI [12])
C0034072 (UMLS CUI [13,1])
C0205082 (UMLS CUI [13,2])
C0017551 (UMLS CUI [14,1])
C0683607 (UMLS CUI [14,2])
C0022350 (UMLS CUI [15,1])
C0683607 (UMLS CUI [15,2])
Study Subject Participation Status | Investigational New Drugs
Item
5. enrolled or planning to be enrolled in another clinical trial of an investigational agent while participating in this study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Safety Assessment Receive Unable | Tolerability Study Receive Unable
Item
6. unable to receive safety and tolerability assessments.
boolean
C0549076 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C3274448 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial